Drug Trial Radar · NCT06119685
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
128
Planned (sponsor's estimate)
Start
Oct 25, 2023
Primary completion
Dec 30, 2025
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Indapta Therapeutics, INC.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Conditions
- NHL
- Multiple Myeloma
- Blood Cancer
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
Interventions
IDP-023Drug
NK cell therapy
RituximabDrug
Anti-CD20 antibody therapy
DaratumumabDrug
Anti-CD38 antibody therapy
Interleukin-2Drug
Immune cytokine
CyclophosphamideDrug
Lymphodepleting chemotherapy
FludarabineDrug
Lymphodepleting chemotherapy
MesnaDrug
Chemoprotectant
IsatuximabDrug
Anti-CD38 antibody therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)Time frame: 1 year
- Incidence of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1)Time frame: up to 21 days
- Nature of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1)Time frame: up to 21 days
- Incidence of dose-limiting toxicities (DLTs) of IDP-023 in combination with Isatuximab, Daratumumab or Rituximab - (Phase 1)Time frame: up to 35 days
- Nature of dose-limiting toxicities (DLTs) of IDP-023 in combination with Isatuximab, Daratumumab or Rituximab - (Phase 1)Time frame: up to 35 days
- Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)Time frame: 1 year
- For MM: Anti-tumor activity by objective response rate (ORR), complete response (CR), stringent complete response (sCR), very good partial response (VGPR), and partial response (PR) - (Phase 2)Time frame: 2 years
- For NHL: Anti-tumor activity by objective response rate (ORR) - (Phase 2)Time frame: 2 years
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center
Lake Mary, Florida · Withdrawn
Emory University Hospital
Atlanta, Georgia · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
NYP/Weill Cornell Medical Center
New York, New York · Withdrawn
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina · Recruiting
University Hospitals Cleveland
Cleveland, Ohio · Recruiting
Providence Cancer Institute Franz Clinic
Portland, Oregon · Withdrawn
Rhode Island Hospital
Providence, Rhode Island · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.